Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events

Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events

MPA is clinically administered as morfolinoethyl ester (mycophenolate mofetil, MMF) or, more recently, as a salt (enteric-coated mycophenolate sodium). It is a fermentation product of Penicillium brevicompactum and other analogue fungi, identified by Gosio in 1893 as a weak antibacterial agent; in 1...

Full description

Bibliographic Details
Main Authors: G.F. Ferraccioli, M. De Santis, G. Zizzo
Format: Article
Language:English
Published: PAGEPress Publications 2011-06-01
Series:Reumatismo
Online Access:http://www.reumatismo.org/index.php/reuma/article/view/469
id doaj-d95f4892d66c48cb8bbe7d5c32269757
record_format Article
spelling doaj-d95f4892d66c48cb8bbe7d5c322697572020-11-25T00:27:59ZengPAGEPress PublicationsReumatismo0048-74492240-26832011-06-016229110010.4081/reumatismo.2010.91Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse eventsG.F. FerraccioliM. De SantisG. ZizzoMPA is clinically administered as morfolinoethyl ester (mycophenolate mofetil, MMF) or, more recently, as a salt (enteric-coated mycophenolate sodium). It is a fermentation product of Penicillium brevicompactum and other analogue fungi, identified by Gosio in 1893 as a weak antibacterial agent; in 1969 Franklin and Cook discovered its capacity to inhibit the inosine mono phosphate dehydrogenase (IMPDH), an enzyme involved in purine nucleotide synthesis (1)...http://www.reumatismo.org/index.php/reuma/article/view/469
collection DOAJ
language English
format Article
sources DOAJ
author G.F. Ferraccioli
M. De Santis
G. Zizzo
spellingShingle G.F. Ferraccioli
M. De Santis
G. Zizzo
Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events
Reumatismo
author_facet G.F. Ferraccioli
M. De Santis
G. Zizzo
author_sort G.F. Ferraccioli
title Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events
title_short Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events
title_full Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events
title_fullStr Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events
title_full_unstemmed Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events
title_sort mycophenolic acid in rheumatology: mechanisms of action and severe adverse events
publisher PAGEPress Publications
series Reumatismo
issn 0048-7449
2240-2683
publishDate 2011-06-01
description MPA is clinically administered as morfolinoethyl ester (mycophenolate mofetil, MMF) or, more recently, as a salt (enteric-coated mycophenolate sodium). It is a fermentation product of Penicillium brevicompactum and other analogue fungi, identified by Gosio in 1893 as a weak antibacterial agent; in 1969 Franklin and Cook discovered its capacity to inhibit the inosine mono phosphate dehydrogenase (IMPDH), an enzyme involved in purine nucleotide synthesis (1)...
url http://www.reumatismo.org/index.php/reuma/article/view/469
work_keys_str_mv AT gfferraccioli mycophenolicacidinrheumatologymechanismsofactionandsevereadverseevents
AT mdesantis mycophenolicacidinrheumatologymechanismsofactionandsevereadverseevents
AT gzizzo mycophenolicacidinrheumatologymechanismsofactionandsevereadverseevents
_version_ 1725337440966672384

Similar Items